HDAC1-IN-11

HDAC1-IN-11 (Compound 6) is a HDAC1 inhibitor with an IC50 of 106.6 nM. HDAC1-IN-11 inhibits the expression of Sp1 and RAD51, thereby inducing Caspase-dependent apoptosis. HDAC1-IN-11 has antitumor activity and sensitizes Etoposide (HY-13629) and Gemcitabine (HY-17026), promoting synergistic death of NSCLC cells through the inhibition of homologous recombination and non-homologous end joining (NHEJ) pathways involved in DNA DSB repair. HDAC1-IN-11 can be used for chemotherapy of cancers like NSCLC research[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; Caspase; DNA/RNA Synthesis; HDAC; RAD51

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics

Field of Research

Cancer

Smiles

NC1=CC=CC=C1NC(C2=CC=C(C=C2)CN3C(N(C(C4=CC=CC=C43)=O)CCC5=CC=CC=C5)=O)=O

Molecular Formula

C30H26N4O3

Molecular Weight

490.55

References & Citations

[1]Huang HC, et al. Establishing a noncanonical zinc-binding group as a selective histone deacetylase inhibitor and possible novel anticancer agent. Bioorg Chem. 2025 Aug 27;165:108917.